Comparison of Four64Cu-Labeled Somatostatin Analogues in Vitro and in a Tumor-Bearing Rat Model:  Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted Radiotherapy‖

1999 ◽  
Vol 42 (8) ◽  
pp. 1341-1347 ◽  
Author(s):  
Jason S. Lewis ◽  
Michael R. Lewis ◽  
Ananth Srinivasan ◽  
Michelle A. Schmidt ◽  
Jian Wang ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Rat Model ◽  
Positron Emission Tomography Imaging ◽  
Somatostatin Analogues ◽  
Emission Tomography ◽  
Targeted Radiotherapy ◽  
Tomography Imaging ◽  
Tumor Bearing ◽  
Positron Emission

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

10.3791/62094 ◽  
2021 ◽  
Author(s):  
Daniele de Paula Faria ◽  
Caroline Cristiano Real ◽  
Larissa Estessi de Souza ◽  
Alexandre Teles Garcez ◽  
Fabio Luis Navarro Marques ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Positron Emission Tomography ◽  
Rat Model ◽  
Positron Emission Tomography Imaging ◽  
Emission Tomography ◽  
Tomography Imaging ◽  
Positron Emission

A Uniquely Modified DKL-based Peptide Probe for Positron Emission Tomography Imaging

2019 ◽  
Vol 25 (1) ◽  
pp. 96-103
Author(s):  
Yi Liu ◽  
Zhengjie Wang ◽  
Xiang Li ◽  
Fei Kang ◽  
Xiaowei Ma ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Positron Emission Tomography Imaging ◽  
Emission Tomography ◽  
Tomography Imaging ◽  
Positron Emission ◽  
Imaging Results ◽  
Gallium 68 ◽  
Tumor Selective

Peptides containing the asparagine-glycine-arginine (NGR) motif can target the tumor neovascular biomarker CD13/aminopeptidase N receptor. D-K6L9 is a tumor-selective anti-cancer peptide. To improve the capacity of NGR peptides to target tumors, we joined the NGR and D-K6L9 peptides to form NKL. Next, we linked 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to NKL and labeled it with gallium 68 (68Ga, t1/2 = 67.7 min) to form 68Ga-DOTA-NKL. This novel probe was characterized in vitro. 68Ga-DOTA-NKL was stable in phosphate buffered saline at room temperature and in human serum at 37°C. We determined that the uptake rate of 68Ga-DOTA-NKL in CD13 receptor-positive 22Rv1 tumor cells was 3.15% ± 0.04 after 2 h, and tested 68Ga-DOTA-NKL using positron emission tomography (PET)/computed tomography imaging in vivo. MicroPET imaging results revealed that 22Rv1 tumor uptake of 68Ga-DOTA-NKL was 8.69 ± 0.20, 6.61 ± 0.22, 3.85 ± 0.06, and 1.41 ± 0.23 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1, 2, and 3 h postinjection (pi), respectively. The tumor-to-background contrast in the subcutaneous human prostate cancer 22Rv1 mouse model was 9.97 ± 1.90. The 68Ga-DOTA-NKL probe has combined tumor-targeting and tumor-selective properties, and may be used to diagnose CD13-positive tumors.

scholarly journals Synthesis of a DOTA-C-glyco bifunctional chelating agent and preliminary in vitro and in vivo study of [68Ga]Ga-DOTA-C-glyco-RGD

RSC Advances ◽  
2021 ◽  
Vol 11 (13) ◽  
pp. 7672-7681
Author(s):  
Floriane Mangin ◽  
Charlotte Collet ◽  
Valérie Jouan-Hureaux ◽  
Fatiha Maskali ◽  
Emilie Roeder ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Cancer Diagnosis ◽  
Positron Emission Tomography Imaging ◽  
Chelating Agent ◽  
Emission Tomography ◽  
Tomography Imaging ◽  
Bifunctional Chelating Agent ◽  
Positron Emission

A carbohydrate containing [68Ga]Ga-DOTA-RGD tracer was designed and demonstrated promising results for cancer diagnosis by positron emission tomography imaging.

Sign in / Sign up

Export Citation Format

Share Document